Coherus Oncology Reports Q4 Earnings Loss

The biotech company missed revenue forecasts despite full-year profitability.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Coherus Oncology, a drug development company based in Redwood City, California, reported a loss of $37.6 million in its fourth quarter. The company posted revenue of $12.7 million in the period, which fell short of analyst expectations of $13.1 million. However, for the full year, Coherus reported a profit of $168 million, or $1.43 per share, on $42.2 million in revenue.

Why it matters

Coherus Oncology's quarterly earnings results provide insight into the financial performance and development progress of the company's drug pipeline. As a biotech firm, Coherus' quarterly and annual financials are closely watched by investors and industry analysts to gauge the company's growth trajectory and prospects.

The details

Coherus Oncology reported a loss of 31 cents per share in the fourth quarter, with losses adjusted for one-time items coming to 34 cents per share. The company's revenue of $12.7 million in the quarter missed the $13.1 million expected by analysts surveyed by Zacks. However, for the full year, Coherus reported a profit of $168 million, or $1.43 per share, on $42.2 million in revenue.

  • Coherus Oncology reported its Q4 and full-year 2025 earnings on March 9, 2026.

The players

Coherus Oncology, Inc.

A biopharmaceutical company focused on developing and commercializing innovative immunotherapies to treat cancer.

Got photos? Submit your photos here. ›

The takeaway

Coherus Oncology's mixed financial results, with a quarterly loss but annual profitability, highlight the challenges and volatility inherent in the biotech industry as companies navigate drug development and commercialization.